[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE323766T1 - Glykosylierte leptinzusammensetzungen und zugehörige verfahren - Google Patents

Glykosylierte leptinzusammensetzungen und zugehörige verfahren

Info

Publication number
ATE323766T1
ATE323766T1 AT00911784T AT00911784T ATE323766T1 AT E323766 T1 ATE323766 T1 AT E323766T1 AT 00911784 T AT00911784 T AT 00911784T AT 00911784 T AT00911784 T AT 00911784T AT E323766 T1 ATE323766 T1 AT E323766T1
Authority
AT
Austria
Prior art keywords
proteins
glycosylated
compositions
glycosylated leptin
leptin
Prior art date
Application number
AT00911784T
Other languages
English (en)
Inventor
Frances H Martin
Steven G Elliott
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE323766T1 publication Critical patent/ATE323766T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00911784T 1999-02-12 2000-02-11 Glykosylierte leptinzusammensetzungen und zugehörige verfahren ATE323766T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
ATE323766T1 true ATE323766T1 (de) 2006-05-15

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911784T ATE323766T1 (de) 1999-02-12 2000-02-11 Glykosylierte leptinzusammensetzungen und zugehörige verfahren

Country Status (11)

Country Link
EP (1) EP1151102B1 (de)
JP (1) JP4841037B2 (de)
AT (1) ATE323766T1 (de)
AU (1) AU781460B2 (de)
CA (1) CA2359840C (de)
CY (1) CY1107470T1 (de)
DE (1) DE60027409T2 (de)
DK (1) DK1151102T3 (de)
ES (1) ES2257287T3 (de)
PT (1) PT1151102E (de)
WO (1) WO2000047741A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002321557B2 (en) * 2001-08-29 2006-03-30 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
WO2003034996A2 (en) * 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
JP5433133B2 (ja) 2003-01-22 2014-03-05 デューク・ユニヴァーシティ リソソームポリペプチドを発現するための改善された構築物
JP4809227B2 (ja) 2003-09-26 2011-11-09 メルク セローノ ソシエテ アノニム タンパク質の産生に使用するためのリーダー配列
PL2586456T3 (pl) 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
CN102099048A (zh) 2008-05-21 2011-06-15 纽若泰兹公司 用于治疗与神经原纤维缠结有关的进行性认知障碍的方法
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
KR20120024529A (ko) 2008-11-04 2012-03-14 니콜라오스 테자프시디스 신경섬유 매듭 및 아밀로이드 베타의 축적으로부터 기인하는 진행성 인지 기능 장애의 치료용 렙틴 조성물 및 치료 방법
DK2621515T3 (en) 2010-09-28 2017-07-17 Aegerion Pharmaceuticals Inc Chimeric seal-human leptin polypeptide with increased solubility
CA2869190C (en) 2012-05-17 2019-11-19 Extend Biosciences, Inc. Vitamin d as a targeting group for therapeutic peptides
DK2900230T3 (en) 2012-09-27 2018-11-12 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
JP6672157B2 (ja) 2013-11-26 2020-03-25 ザ チルドレンズ メディカル センター コーポレーション 肥満を処置するための化合物およびその使用方法
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
IL192290A0 (en) * 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU4766596A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Ob gene product antibodies
DK0866720T3 (da) * 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
WO1998007446A1 (en) * 1996-08-23 1998-02-26 Eli Lilly And Company Protein formulations
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs
ES2228082T3 (es) * 1998-08-10 2005-04-01 Amgen Inc. Conjugados dextrano-leptina, composiciones farmaceuticas y metodos relacionados.
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
DE60027409T2 (de) 2007-04-12
CA2359840C (en) 2012-10-23
AU3362300A (en) 2000-08-29
CY1107470T1 (el) 2012-12-19
AU781460B2 (en) 2005-05-26
JP2002536018A (ja) 2002-10-29
EP1151102A1 (de) 2001-11-07
EP1151102B1 (de) 2006-04-19
PT1151102E (pt) 2006-07-31
WO2000047741A1 (en) 2000-08-17
ES2257287T3 (es) 2006-08-01
DE60027409D1 (de) 2006-05-24
JP4841037B2 (ja) 2011-12-21
DK1151102T3 (da) 2006-05-29
CA2359840A1 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
CY1107470T1 (el) Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι
AU2001254624A1 (en) Human coagulation factor vii variants
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
EP1484339A3 (de) Kallikreinhemmende "Kunitz-Domäne"Proteine dafür kodierende Nukleinsäure
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
YU48703A (sh) Novi interferonu beta-slični molekuli
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
WO2003059934A3 (en) Albumin fusion proteins
DE60307701D1 (de) Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
EP0797999A3 (de) Fettleibigkeitprotein-Formulierungen
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
WO1995025171A3 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
EP0369816A3 (de) Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
CA2002833A1 (en) Interferon-gamma binding proteins
BR0211991A (pt) HormÈnio do crescimento humano modificado
WO2002007514A3 (en) Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
DE69529235D1 (de) Menschliche dnase i varianten
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1151102

Country of ref document: EP